Identifying and evaluating biomarkers, including PD-L1 status, tumor mutational burden (TMB), and other factors related to the microenvironment and genomic background, are crucial for shaping personalized treatment strategies and effectively stratifying patients. This evidence concerns the gene CD274 and neoplasm.